Manufacturing

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

James Hamilton, president of Sharp Sterile, discussed innovation in products associated with sterile manufacturing and industry trends that are driving growth.

CPHI Milan 2024: Growth and Challenges in the Sterile Injectables Market

Articles

When the expansion is completed, Piramal expects manufacturing capacity to be increased by the first quarter of 2027 from 104 product batches per year to more than 240.

Piramal to Invest $80 Million in Sterile Injectables Facility Expansion in Kentucky

Feliza Mirasol is the science editor for 

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing

Mary Van Gaasbeck, technical services specialist, LS Equipment and Services, at STERIS Life Sciences, notes that automation is key when it comes to effective sterile powder transfer of parenteral drug products.

Taking a Deeper Look at Sterile Powder Transfer in Aseptic Fill/Finish of Parenterals (INTERPHEX 2024)

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Automating the Future of Fill/Finish

The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.

Nelson Labs Creates Center of Excellence for Parenteral and Ophthalmic Drug Manufacturing

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Driving Dosage Form Developments

Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.

Manufacturing, Parenterals and Injectables